



Veradigm Adds Social Determinants of Health and Mortality Data to EHR Database to Allow Deeper Insights into the Patient Journey

January 13, 2025

Veradigm Network EHR (VNEHR) Data includes over 154M unique patients nationally, transforming research capabilities and advancing patient care

CHICAGO--(BUSINESS WIRE)--Jan. 13, 2025--

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced the integration of two new datasets to expand the depth and breadth of [Veradigm Network EHR \(VNEHR\) Data](#), one of the nation's most comprehensive ambulatory electronic health record (EHR) databases. The database enrichment includes social determinants of health (SDoH) and mortality data, giving researchers new insights to tackle health disparities, enhance real-world evidence (RWE) studies, improve care, and offer strategic and operational benefits for life science companies.

"With our NLP-derived SDoH and mortality data, life sciences organizations gain a competitive advantage by moving beyond traditional clinical measures to explore the full spectrum of factors influencing patient health," said Stuart Green, Vice President & General Manager of Life Sciences Business for Veradigm. "This innovation unlocks new research opportunities and can position organizations as leaders in advancing health equity and improving patient outcomes."

Currently, **80%** of critical patient information is locked within unstructured data, including clinical notes, leading to an incomplete view of a patient's health journey. However, with VNEHR Data, the combination of scale, diversity, and advanced natural language processing (NLP) technology provides research-ready, de-identified data optimized for life science, public health, and academic research. Now with a complete view, these stakeholders can gain deeper insights into therapeutic decisions, disease progression, and patient outcomes across various therapeutic areas.

The new NLP-derived SDoH data within VNEHR Data provides researchers with insights into socioeconomic, environmental and behavioral factors, including income levels, education, housing stability, and social support, areas that can be overlooked in traditional clinical data. By extracting nuanced SDoH information, Veradigm is enabling researchers to take a more holistic view of the patient and explore the intersection of clinical and social factors influencing health outcomes. This will help life science organizations enhance treatment insights, advance evidence generation, support market access strategies, and refine patient segmentation.

In addition, ambulatory EHR mortality data provides researchers with meaningful insights into patient populations and associated outcomes within outpatient care settings. This foundational dataset helps life science organizations enhance RWE generation by demonstrating long-term safety and efficacy and supporting post-market surveillance by identifying mortality trends associated with drug or device use. Additional benefits include accelerating drug development through improved identification of patient populations at risk, demonstrating value to payers and providers through added evidence to support reimbursement decisions, and enhancing precision medicine efforts by combining mortality data with genetic and biomarker information.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, *Insightfully*, visit www.veradigm.com, or find Veradigm on [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#), and [YouTube](#).

© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250113137490/en/): <https://www.businesswire.com/news/home/20250113137490/en/>

Investors:

Jenny Gelinias
312-506-1237
Jenny.Gelinias@veradigm.com

Media:

Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@veradigm.com

Source: Veradigm